GLP-1 medications — semaglutide and tirzepatide — are the most effective prescription weight loss drugs available in 2026. If you are considering one of them for the first time, you likely have questions about how they work, what the experience feels like week by week, what side effects to expect and how to manage them, what to eat, how to choose a provider, and whether compounded or brand-name is right for you.
This guide answers all of those questions in clinical depth. By the end, you will know exactly what to expect from starting GLP-1 treatment, how to set yourself up for success in the first 90 days, and how to evaluate your options before committing to a program.
What Are GLP-1 Medications and How Do They Work?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone your body naturally produces in the small intestine in response to food. GLP-1 plays a central role in regulating appetite and blood sugar: it signals the brain to reduce hunger, slows the rate at which food moves from the stomach into the small intestine, and stimulates the pancreas to release insulin in proportion to blood glucose levels.
The pharmaceutical versions of GLP-1 — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — are modified versions of this hormone that have been engineered to survive much longer in the body than the natural peptide, which breaks down within minutes. Semaglutide has a half-life of approximately seven days, making once-weekly dosing possible. Tirzepatide is a dual agonist that activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors, producing additive metabolic effects that contribute to its somewhat greater average weight loss compared to semaglutide alone.
The practical result of these mechanisms is that patients taking GLP-1 medications experience significantly reduced appetite, earlier satiety after smaller meals, and reduced food cravings — particularly for high-fat, high-sugar foods. These effects are not willpower or behavioral discipline; they are pharmacological. The medication changes the signaling environment your brain operates in. Most patients describe the experience as food simply becoming less important, less urgent, and less pleasurable in ways that make eating less feel natural rather than effortful.
What the Clinical Trials Show: Realistic Expectations
The STEP 1 trial (Wilding et al., NEJM, 2021) enrolled 1,961 adults with obesity and randomized them to semaglutide 2.4 mg weekly or placebo over 68 weeks. The semaglutide group achieved a mean body weight reduction of 14.9% — and approximately one-third of participants lost 20% or more of their body weight. These are averages: some patients lose significantly more, some lose less. The outcomes at the full maintenance dose of 2.4 mg, reached after approximately 16 weeks of titration, represent what patients can realistically aim for over a full treatment course.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) demonstrated tirzepatide producing mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) over 72 weeks — with the highest-dose responders averaging 22.5% body weight loss. Tirzepatide's superior average outcomes make it the preferred agent for patients who need maximum efficacy, though it costs more and the two medications have not been directly compared head-to-head in a published RCT.
Important context: the first month of GLP-1 treatment is the starting dose adjustment phase, not the period of maximum weight loss. Most patients lose 2 to 4 pounds in month one. The more significant losses occur as doses escalate over months two through five. Setting accurate expectations for the early phase prevents discouragement in the period before you reach your therapeutic dose.
Semaglutide vs. Tirzepatide: Which Is Right for a First-Time Patient?
First-time GLP-1 patients have two primary options: semaglutide (the active ingredient in Wegovy and Ozempic) or tirzepatide (the active ingredient in Zepbound and Mounjaro). Both are once-weekly subcutaneous injections. Both work through GLP-1 receptor pathways. The differences in mechanism, average outcomes, and cost are worth understanding before you decide.
Semaglutide — Key Facts
- Mechanism: Pure GLP-1 receptor agonist
- Starting dose: 0.25 mg weekly
- Maintenance dose: 1.0–2.4 mg weekly
- Titration period: ~16 weeks to full dose
- Average weight loss: ~15% body weight (STEP 1)
- At Luma Health: $197/month flat
- Best for: Most first-time patients; strong evidence base
Tirzepatide — Key Facts
- Mechanism: Dual GIP + GLP-1 receptor agonist
- Starting dose: 2.5 mg weekly
- Maintenance dose: 5–15 mg weekly
- Titration period: ~20 weeks to full dose
- Average weight loss: ~20% body weight (SURMOUNT-1)
- At Luma Health: $297/month flat
- Best for: Patients with higher weight loss goals or lower sema response
For most first-time patients, semaglutide is a reasonable starting point. It has the longer clinical track record, a well-established side effect profile, and achieves meaningful weight loss for the majority of patients who adhere to treatment. Tirzepatide's superior average outcomes make it a compelling choice for patients who want maximum efficacy from the start or who have a significant amount of weight to lose. Cost is a factor for many patients: at Luma Health, the $100 monthly difference ($197 vs. $297) adds up to $1,200 annually, which over a 12 to 18 month treatment course is a meaningful consideration. See our detailed semaglutide vs. tirzepatide comparison for more clinical depth on this decision.
What to Expect: Week-by-Week Timeline for First-Time GLP-1 Patients
Understanding the typical experience week by week helps first-time patients calibrate expectations and avoid the two most common early pitfalls: expecting too much too soon in the first four weeks, and quitting before reaching the dose where the most significant outcomes occur. The following timeline reflects the standard semaglutide experience — tirzepatide follows a similar pattern with a slightly longer titration schedule.
1–4
Starting Dose Phase (0.25 mg semaglutide weekly)
The starting dose is not a therapeutic dose — it is a tolerance phase designed to let your body adapt to the medication before escalation. Most patients notice mild appetite reduction but relatively modest effects on hunger. Side effects are most common in this phase: nausea, mild fatigue, and loose stools are reported by a significant minority of patients in weeks one and two, typically peaking around days two to three after the first injection and diminishing over the following week. Weight loss in this phase is typically 2 to 4 pounds — encouraging but not dramatic. Do not judge the medication's potential based on this phase.
5–8
First Dose Increase (0.5 mg weekly)
At week five, your provider increases your dose to 0.5 mg weekly. Most patients experience a brief recurrence of mild GI symptoms in the first one to two weeks at the new dose, then adaptation. Appetite suppression becomes noticeably more pronounced at this level. Many patients describe the 0.5 mg phase as the first time they genuinely feel the medication changing how food relates to them — meals feel satisfying with less food, and the urgency around eating diminishes. Cumulative weight loss by the end of this phase is typically 5 to 8 pounds for most patients.
9–16
Mid-Titration Phase (1.0 mg weekly)
The 1.0 mg dose is often where patients who were not sure whether the medication was "working" become convinced. Appetite suppression at this level is substantially stronger than at 0.5 mg for most patients. Food noise — the background mental chatter about eating, cravings, and what to eat next — quiets significantly. Patients often report forgetting to eat or finding previously irresistible foods uninteresting. Cumulative weight loss by the end of this phase is typically 8 to 14 pounds for adherent patients. Some patients' providers stabilize them at 1.0 mg if they are achieving good results; others continue to higher doses.
17–24
Higher Maintenance Phase (1.7 mg and 2.4 mg weekly)
Patients titrating to 1.7 mg and 2.4 mg weekly reach the full maintenance dose range where the STEP 1 trial's 14.9% average weight loss was documented. Not every patient needs or tolerates the maximum dose — some achieve their goals at 1.0 mg and their provider stabilizes them there. For patients who do reach 2.4 mg, this is the dose level where the most significant and sustained weight loss typically occurs. By month six at or near maintenance dose, cumulative weight loss of 10% to 20% of starting body weight is realistic for adherent patients.
6–18
Long-Term Maintenance
GLP-1 medications work for as long as you take them. The STEP 4 trial demonstrated that patients who discontinued semaglutide after initial weight loss regained approximately two-thirds of the weight lost within one year. This means GLP-1 treatment is not a short-term intervention — it is chronic disease management. Most clinical guidelines support continued treatment for 12 to 24 months minimum, with ongoing reassessment of outcomes and tolerability. Planning your budget and treatment expectations around this timeframe from the start produces better long-term results than approaching GLP-1 as a 90-day program.
Managing Side Effects as a First-Time Patient
GLP-1 side effects are real, common during the titration phase, and manageable for most patients with the right preparation. Understanding which side effects to expect, which are temporary, and which require clinical attention makes the first weeks of treatment considerably more comfortable than going in blind.
Most common in weeks one to two at each new dose. Peaks two to three days post-injection and typically resolves within a week. Eat smaller portions, avoid greasy or spicy foods, and stay upright after eating. Anti-nausea medications like ondansetron may be prescribed for severe cases.
Occurs because semaglutide slows gastric motility throughout the GI tract. Increase water intake to 64–96 oz daily, add fiber (25–30 g/day), and consider a daily magnesium supplement (400 mg). If constipation persists beyond two weeks, contact your provider.
Some patients experience loose stools rather than constipation, particularly early in treatment. Usually self-limiting within the first week at each dose. Staying hydrated and eating easily digestible foods (bananas, rice, toast) can help during acute episodes.
Many patients feel tired in the first one to two days after their weekly injection, particularly during the early titration phase. Scheduling injections on days when you have lower obligations (Friday or Saturday evening, for example) minimizes functional impact.
Often related to reduced caloric intake or inadequate hydration in the early weeks. Ensure you are drinking enough water and maintaining adequate electrolyte intake. Typically resolves within the first four to six weeks of treatment.
Slowed gastric motility can worsen acid reflux in susceptible patients. Avoid large meals, lying down within two hours of eating, and spicy or acidic foods that aggravate reflux. Proton pump inhibitors or H2 blockers may be recommended for persistent cases.
Mild redness, itching, or swelling at the injection site is normal and typically resolves within hours. Rotating injection sites (abdomen, thigh, upper arm) prevents accumulation reactions. If lumps or prolonged swelling develop, contact your provider.
Reported by some patients during rapid weight loss phases, likely related to caloric restriction rather than the medication itself. Usually temporary. Maintaining adequate protein intake (1.2–1.5 g/kg body weight) is the most effective prevention strategy.
What to Eat in Your First Month on GLP-1
GLP-1 medications reduce appetite — they do not dictate what you eat when you do choose to eat. But the foods you choose matter significantly for two reasons: they affect how comfortable you feel on the medication (high-fat, high-sugar meals worsen nausea and GI side effects during titration), and they determine whether the weight you lose comes primarily from fat or from a combination of fat and lean muscle mass.
The most clinically important dietary consideration during GLP-1 treatment is protein intake. Rapid weight loss — which is what GLP-1 medications produce at maintenance doses — is associated with loss of lean muscle mass as well as fat unless protein intake is actively maintained. The Obesity Medicine Association recommends 1.2 to 1.5 grams of protein per kilogram of body weight during medically supervised weight loss. For a 200-pound (91 kg) patient, that translates to approximately 110 to 137 grams of protein daily — a meaningful target when appetite is suppressed.
Practical protein-priority foods that work well during GLP-1 treatment include Greek yogurt, eggs, cottage cheese, lean chicken or turkey, fish and shellfish, legumes (beans, lentils, chickpeas), and protein shakes when solid food is unappealing. These foods are also generally lower in fat, which reduces the risk of nausea during the titration phase. For a complete meal structure guide during GLP-1 treatment, see our detailed guide on what to eat on GLP-1 medication.
In the first four to eight weeks — when side effects are most active — smaller, more frequent meals are generally better tolerated than larger portions. Three to four meals of four to six ounces each, spaced two to three hours apart, keeps blood sugar stable and prevents the overfull feeling that triggers nausea. Staying hydrated with 64 to 96 ounces of water daily is consistently one of the most impactful things patients can do to manage GI symptoms in the early phase.
How to Choose a GLP-1 Provider as a First-Time Patient
The telehealth GLP-1 market has grown significantly and now includes dozens of platforms with varying levels of clinical quality, pricing transparency, pharmacy credibility, and program structure. First-time patients evaluating their options should focus on the following five dimensions before committing to any program.
Verify the compounding pharmacy independently
Ask for the name and state pharmacy board license number of the compounding pharmacy that will prepare your medication. Verify that license number through the relevant state board's public database — do not rely on the provider's assurance alone. A legitimate 503A licensed sterile compounding pharmacy will have a publicly verifiable state board record and will provide their license number without hesitation. Luma Health uses VialsRX, licensed by the Texas State Board of Pharmacy (license #35264, verifiable at pharmacy.texas.gov).
Request the full pricing schedule at every dose tier
Many GLP-1 providers advertise a low starting price that increases at each dose tier as you titrate upward. Ask explicitly: what will I pay at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg? Are consultation fees, shipping, and labs included? Is pricing flat or dose-dependent? Providers with flat-rate pricing — like Luma Health's $197/month regardless of dose — give you cost predictability that dose-tiered providers cannot match.
Confirm US-licensed prescribers review your intake
Your prescription must be issued by a clinician licensed in your state of residence who has reviewed your complete health history — not an offshore review process or an automated approval. Ask the provider explicitly how your intake is reviewed, who issues the prescription, and how you can reach a clinician if you have questions about side effects or need a dose adjustment. Response time and communication channel matter as much as the initial prescription.
Understand the contract and cancellation terms
GLP-1 treatment is a long-term commitment — but life circumstances change. Make sure you understand what happens if you need to pause treatment, if side effects require you to stop, or if you find a better option. Some providers require 6 or 12-month commitments with early termination fees. Others, like Luma Health, operate on a no-contract month-to-month basis with no cancellation penalties. Know the terms before you pay.
Evaluate the ongoing clinical support model
GLP-1 treatment is not a one-time prescription — it involves ongoing dose management, side effect monitoring, and clinical adjustment over 12 to 18 months. Understand how your provider handles dose escalation requests, how quickly they respond to clinical questions, and what happens if you experience a side effect that requires attention. The quality of ongoing clinical support is at least as important as the intake experience.
Compounded vs. Brand-Name: What First-Time Patients Need to Know
The vast majority of first-time GLP-1 patients accessing treatment through telehealth in 2026 will receive compounded semaglutide or tirzepatide rather than the FDA-approved branded versions (Wegovy, Ozempic, Zepbound, Mounjaro). Understanding what compounded means — and what it does not mean — is essential for informed decision-making.
Compounded semaglutide and tirzepatide contain the same active pharmaceutical ingredient as the branded versions. The molecule is identical, the GLP-1 receptor agonist mechanism is identical, and the expected clinical outcomes are equivalent when the medication is properly formulated at the correct concentration. What is different is the manufacturing pathway: branded medications go through the FDA's new drug approval process and are manufactured at scale by pharmaceutical companies. Compounded medications are prepared per individual prescription by licensed 503A sterile compounding pharmacies under state pharmacy board oversight, without the full FDA approval designation that applies to branded products as finished drug products.
The cost difference is substantial. Brand-name Wegovy has a list price of approximately $1,349 per month without insurance. Compounded semaglutide through Luma Health is $197 per month. For patients without insurance coverage of GLP-1 medications — which represents the majority of telehealth patients — compounded options are the only financially accessible path to sustained treatment.
The legitimate quality question with compounded medications is not about the active ingredient but about the manufacturing standards of the specific pharmacy. This is why pharmacy verification — covered in step one of the provider selection checklist above — is the most important consumer protection action a first-time patient can take. A properly licensed, USP 797-compliant 503A sterile compounding pharmacy with documented potency and sterility testing provides meaningful quality assurance that self-directed purchasing from unverified sources cannot.
Your First Injection: Practical Guidance
For patients who have never self-administered an injection before, the first GLP-1 injection is often a source of anxiety that far exceeds the actual experience. Subcutaneous injections — into the fatty tissue just beneath the skin — use very fine needles and are significantly less painful than intramuscular injections or blood draws. Most patients describe the experience as a mild pinch that lasts less than five seconds.
Injection sites for subcutaneous GLP-1 medication include the abdomen (at least two inches from the navel), the outer thigh, and the back of the upper arm. The abdomen is the most commonly used site for first-time injectors because it is easiest to see and control. Rotate injection sites each week to prevent tissue accumulation effects. Your medication will come with detailed injection instructions from your pharmacy, and your clinical team at Luma Health is available to answer questions about technique through the patient portal.
Practical tips for the first injection: take the medication out of the refrigerator 30 minutes before injecting to allow it to reach room temperature, which reduces injection discomfort. Clean the injection site with an alcohol swab and allow it to dry completely before injecting. Pinch the skin gently to lift the subcutaneous tissue away from muscle. Insert the needle at a 45-to-90-degree angle depending on body composition. Inject slowly and evenly, then withdraw the needle and apply gentle pressure with a cotton ball. Do not rub the site after injecting. Dispose of the needle in a sharps container — never in a standard trash bin.
Frequently Asked Questions
How soon will I see results on GLP-1 medication?
Most patients notice some appetite reduction within the first two weeks, but visible weight loss in the first month is typically modest — two to four pounds is realistic at the starting dose. The more meaningful weight loss begins as you titrate upward over months two through five. Patients who expect dramatic results in week one are often disappointed; patients who understand that the first 16 weeks are a titration phase setting up long-term outcomes tend to have much better experiences and persistence. By months four to six at or near a maintenance dose, cumulative weight loss of 10% or more of starting body weight is realistic for adherent patients.
Do I need to change my diet to make GLP-1 work?
GLP-1 medications reduce appetite and promote weight loss independently of dietary changes — they work in the absence of a strict diet. However, what you eat affects how comfortable you feel on the medication and whether the weight you lose comes primarily from fat or from lean muscle. Prioritizing protein (1.2–1.5 g/kg body weight), avoiding large high-fat meals during the titration phase, and staying well hydrated all significantly reduce side effect severity and support better long-term outcomes. The medication changes what feels desirable and manageable to eat; making protein-forward choices within those changed preferences produces the best results.
What if the side effects are too much for me?
If side effects during the titration phase are severe or interfering significantly with daily function, contact your clinical provider before stopping the medication. The most common clinical response to intolerable side effects is a temporary dose hold or a slower titration schedule — extending the time at each dose from four weeks to six to eight weeks before escalating. Anti-nausea medications can be prescribed for persistent nausea. Most patients who push through the first two to four weeks at each new dose find that side effects diminish substantially as the body adapts. Stopping the medication entirely based on early side effects is usually unnecessary and forfeits outcomes that would have been achievable with dose adjustment.
How long do I need to stay on GLP-1 medication?
GLP-1 medications are most effective as long-term chronic therapy rather than short-term interventions. The STEP 4 trial demonstrated that patients who stopped semaglutide after achieving weight loss regained approximately two-thirds of the weight lost within one year of discontinuation. This is not a failure of the medication — it reflects that obesity is a chronic condition requiring ongoing management, similar to how blood pressure medications manage hypertension only while being taken. Most clinical guidelines support GLP-1 treatment for at least 12 to 18 months, with ongoing assessment of outcomes and consideration of continued treatment as long as clinical benefit is maintained. Planning for this timeframe from the start produces better outcomes and financial planning than approaching it as a short-term program.
Can I drink alcohol on GLP-1 medication?
Alcohol is not strictly prohibited with GLP-1 medications, but it warrants caution for several reasons. Semaglutide and tirzepatide can potentiate the hypoglycemic effects of alcohol — meaning blood sugar can drop more than expected, particularly if you have eaten less than usual. Alcohol also acts as a gastric irritant that can worsen nausea and reflux that are already present during the titration phase. Most GLP-1 prescribers recommend minimizing alcohol during treatment — particularly in the first few months — and avoiding it entirely on injection days or the day after. If you choose to drink, eat first, limit to one drink, and avoid high-sugar mixed drinks or frozen cocktails.
Will I need to take GLP-1 medication forever?
Not necessarily, but the research on long-term discontinuation is clear: most patients regain a significant portion of lost weight after stopping. Some patients are able to maintain outcomes through sustained lifestyle changes after discontinuing — particularly if they have used the period on medication to develop lasting dietary and exercise habits. Others require ongoing low-dose maintenance therapy. The decision about when and whether to attempt discontinuation is a clinical one that should be made in partnership with your prescribing provider based on your weight trajectory, metabolic markers, and individual circumstances — not based on a predetermined timeline at enrollment.
How do I start GLP-1 treatment through Luma Health?
The intake process at Luma Health starts with a health questionnaire at start.mylumahealth.com. The questionnaire covers your medical history, current medications, weight history, and health goals. A licensed clinician from Wasef Health, PC reviews your intake, confirms eligibility using FDA-aligned criteria (BMI of 30 or greater, or BMI of 27 or greater with a weight-related comorbidity), screens for contraindications, and prescribes the appropriate medication and starting dose if you qualify. The review typically takes 24 to 48 hours. Your prescription is then sent to VialsRX, Luma Health's licensed 503A compounding pharmacy in Houston, TX, and shipped directly to your home within three to seven days of approval. Luma Health's pricing is flat — $197/month for semaglutide, $297/month for tirzepatide — with no dose-tier increases, no contracts, and free shipping.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. PubMed
- FDA. Wegovy (semaglutide) Prescribing Information. 2023. FDA.gov
- FDA. Zepbound (tirzepatide) Prescribing Information. 2023. FDA.gov
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. PubMed
- Obesity Medicine Association. Protein Recommendations During Medically Supervised Weight Loss. 2023. obesitymedicine.org
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy